24 Amendments of Margarita DE LA PISA CARRIÓN related to 2020/2071(INI)
Amendment 60 #
Draft opinion
Paragraph 1 a (new)
Paragraph 1 a (new)
1 a. Calls the Commission and Member States to provide an environment that ensures Europe continues to be an attractive location for R&D investment and industrial development in the pharmaceutical industry to respond to potential needs;
Amendment 62 #
Draft opinion
Paragraph 1 b (new)
Paragraph 1 b (new)
1 b. Stresses the need to maintain open borders via Green Lanes, facilitating crossing borders to those pharmaceutical or medical companies distributing and supplying medicines and/or personal protection equipment (PPE), to avoid possible shortages of medicines;
Amendment 68 #
Draft opinion
Paragraph 2
Paragraph 2
2. Calls on the Commission to consider proposing requirements for the pharmaceutical industry to ensure that its supply chain is diversified and put in place a medicine shortage risk mitigation plan to manage any vulnerabilities in and risks to the supply chain; notes the importance for the industry to have the capacity of increasing its production to be able to meet with the sudden surge in the demand due to critical situations;
Amendment 72 #
Draft opinion
Paragraph 2 a (new)
Paragraph 2 a (new)
Amendment 77 #
Draft opinion
Paragraph 2 b (new)
Paragraph 2 b (new)
2 b. Stresses the need to establish proper pandemic preparedness plans under medical supervision for critical medicines at EU level based on solidarity between Member States, and ensuring that non-pandemic related medicines continue to reach the patients in need;
Amendment 92 #
3 a. Calls on the Commission and Member States to re-balance stocks based on patients’ and hospitals´ needs instead of stockpiling; notes that to ensure a fair allocation at European level, it is necessary to have an equitable distribution of medicines based on shared protocols on the use of medicines to give priority to those who urgently require it;
Amendment 92 #
Motion for a resolution
Recital C
Recital C
C. whereas the loss of European sovereignty and independence in the health sector is linked to the relocation of production, with 40% of medicinal end products marketed in the EU now originating in third countries; whereas the only way to save money is to rely heavily on subcontractors to produce pharmaceutical raw materials in Asia, where labour costs and environmental standards are lower, with the result that 80% of active ingredients are manufactured outside the EU, mainly in China and India;
Amendment 100 #
Motion for a resolution
Recital C a (new)
Recital C a (new)
Ca. whereas the EU dependency on third countries in production and supply of medicines place the EU in risk of shortages; whereas its consequences have been showed during the pandemic;
Amendment 170 #
Motion for a resolution
Recital I
Recital I
Amendment 224 #
Motion for a resolution
Paragraph 2
Paragraph 2
2. Points out that, while public health policies are a Member State matter, it is incumbent upon the EU to coordinllaborate and complement national measures to guarantee affordable and high-quality health services for European citizens;
Amendment 241 #
Motion for a resolution
Paragraph 3
Paragraph 3
3. Stresses the need for health policies to focus on patients’ interests without allowing any discrimination in the access to medicines and treatments, such as the age of the patient, and for closer cooperation between Member States;
Amendment 254 #
Motion for a resolution
Paragraph 3 a (new)
Paragraph 3 a (new)
3a. Stresses residence for the elderly have been the most affected by the pandemic; regrets the lack of access to medicines they had in many cases to treat patients in the first stage of the illness;
Amendment 258 #
Motion for a resolution
Subheading 1
Subheading 1
Securing supplies in the interests of patients and restoring health sovereigntthe European capacity of health production and supply
Amendment 288 #
Motion for a resolution
Paragraph 4
Paragraph 4
4. Calls on the Commission and the Member States to take whatever action is needed to restore European health sovereigntyindependence and local pharmaceutical manufacturing, giving priority to essential and strategic medicines; calls on the Commission to map out potential production sites in the EU;
Amendment 299 #
Motion for a resolution
Paragraph 4 a (new)
Paragraph 4 a (new)
4a. Notes the importance for the industry to have the capacity of increasing its production to be able to meet with the sudden surge in the demand due to critical situations, understanding demand as the total of patients in need, without any kind of discrimination, especially by age;
Amendment 364 #
Motion for a resolution
Paragraph 6 a (new)
Paragraph 6 a (new)
6a. Calls on the Commission and Member States to provide an environment that ensures Europe as an attractive location for R&D investment and industrial development in the pharmaceutical industry;
Amendment 431 #
Motion for a resolution
Paragraph 9
Paragraph 9
9. Calls on the Commission and the Member States to create one or more European non-profit pharmaceutical undertakings which operate in the public interest to manufacture priority medicines of strategic importance for health care to complement the supply, in order to avoid possible shortages of medicines in case of emergency; stresses the key contribution that can be made by new technologies and artificial intelligence in enabling European laboratory researchers to form networks and share their objectives and findings;
Amendment 486 #
Motion for a resolution
Subheading 2
Subheading 2
More vigorous action at European level to better coordinllaborate and supplement Member States’ health policies
Amendment 495 #
Motion for a resolution
Paragraph 12
Paragraph 12
12. Recommends the introduction of centralised management of information to bring about greater transparency in the distribution chain and the creation of a European supply management unit tasked with developingdefinition and development of a European strategy to prevent manage and resolve breaks in supply;
Amendment 513 #
Motion for a resolution
Paragraph 12 a (new)
Paragraph 12 a (new)
12a. Stresses the need to maintain open borders via green lanes, facilitating crossing borders to those pharmaceutical or medical companies distributing and supplying medicines and/or personal protection equipment (PPE), to avoid possible shortages of medicines;
Amendment 569 #
Motion for a resolution
Paragraph 15
Paragraph 15
15. Calls on the Commission and the Member States to adopt a joint definition of ‘medicines of strategic importance for health care’ and of ‘criticality’, emphasising the value of these medicines for public health, the lack of alternatives and the vulnerability of the production chain; calls for a European regulatory authority to be designated to carry out the task of setting quotas for the allocation of medicines from that reserve to the Member States;
Amendment 666 #
Motion for a resolution
Paragraph 18 a (new)
Paragraph 18 a (new)
18a. Calls on the Commission and Member States to re-balance stocks based on patients’ and hospitals’ needs instead of stockpiling; notes that to ensure a fair allocation at EU level, it is necessary to have an equitable distribution of medicines based on shared protocols on the use of medicines to give priority to those who urgently require it;
Amendment 672 #
Motion for a resolution
Paragraph 18 b (new)
Paragraph 18 b (new)
18b. Stresses the need to establish proper pandemic preparedness plans under medical supervision for critical medicines at EU level based on solidarity between Member States, and ensuring that non-pandemic related medicines continue to reach the patients in need;
Amendment 674 #
Motion for a resolution
Paragraph 18 c (new)
Paragraph 18 c (new)
18c. Considers that the European Centre for Disease Control (ECDC) should release modelling data about the likely progression of the pandemic in each Member State in order to anticipate demand to adjust the manufacturing capacity and distribution channels accordingly to supply those medicines needed to the right regions at the right time;